Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics
09:43am, Thursday, 03'rd Mar 2022 Zacks Investment Research
Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
09:20am, Thursday, 03'rd Mar 2022
The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET
Catalyst to get 3 more US patents for rare autoimmune disorder drug Firdapse
07:01pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Catalyst Pharmaceuticals <> said the U.S. Patent and Trademark Office will issue three patents related to its drug Firdapse, used to treat Lambert-Eaton myasthenic syndrome…
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
02:40pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
02:30pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
01:03pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
10:42am, Wednesday, 02'nd Mar 2022
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
10:42am, Wednesday, 02'nd Mar 2022
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
02:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know
03:00pm, Monday, 28'th Feb 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the posit
What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"
01:50pm, Monday, 28'th Feb 2022 Zacks Investment Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
04:09pm, Friday, 25'th Feb 2022 Zacks Investment Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
04:05pm, Friday, 25'th Feb 2022 Zacks Investment Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
03:37pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
01:03pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders
